

DAFTAR PUSTAKA

1. Permono B, Ugrasena I, Supriyadi E. Leukemia Akut. In: Windiastuti E, Movieta Y, Mulatsih S, Sudarmanto B, Dewa IGU, editors. Buku Ajar Hematologi Onkologi Anak. Edisi Revisi. Jakarta Pusat: Badan Penerbit Ikatan Dokter Anak Indonesia; 2018. p. 276–91.
2. O'Connor D, Bate J, Wade R, Clack R, Dhir S, Hough R, et al. Infection-related mortality in children with acute lymphoblastic leukemia: An analysis of infectious deaths on UKALL2003. *Blood*. 2014 Aug 14;124(7):1056–61.
3. Jackmann N, Englund S, Frisk P, Mäkitie O, Utriainen P, Mörtberg A, et al. The human cathelicidin hCAP-18 in serum of children with haemato-oncological diseases. *Br J Haematol*. 2022;198(6):1023–31.
4. Nagaoka I, Tamura H, Reich J. Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model. *Int J Mol Sci* [Internet]. 2020 Aug 19;21(17):5973.
5. Gunawan Stefanus, Frans MJ. Sel Darah Putih, Gangguan Granulosit. In: Widiastuti E, Movieta Y, Mulatsih S, Sudarmanto B, Dewa IGU, editors. Buku Ajar Hematologi onkologi Anak. Edisi Revisi. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2018. p. 117–28.
6. Ye Y, Carlsson G, Agholme MB, Karlsson-Sjöberg J, Yucel-Lindberg T, Pütsep K, et al. Pretherapeutic Plasma Pro- and Anti- Inflammatory Mediators Are Related to High Risk of Oral Mucositis in Pediatric Patients with Acute Leukemia: A Prospective Cohort Study. *PLoS One*. 2013 May 31;8(5).
7. Pütsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. *Lancet* [Internet]. 2002 Oct 12;360(9340):1144–9.
8. Zecha JAEM, Raber-Durlacher JE, Laheij AMGA, Westermann AM, Epstein JB, de Lange J, et al. The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive

chemotherapy. Vol. 27, Supportive Care in Cancer. Springer Verlag; 2019. p. 3667–79.

9. Shibl A, Sayed H, Ali A, Mahmoud D, Abdelhamid O. Long term survival outcome of childhood acute lymphoblastic leukemia treated with modified TXIIB protocol at South Egypt Cancer Institute. *International Journal of Cancer and Biomedical Research*. 2021 Sep 25;0(0):0–0.
10. Rivera GK, Ribeiro RC. Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships. Vol. 7, *Expert Review of Hematology*. Expert Reviews Ltd.; 2014. p. 649–57.
11. Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. *Radiat Res*. 2013 Mar;179(3):361–82.
12. Hansen BA, Wendelbo Ø, Bruslerud Ø, Hemsing AL, Mosevoll KA, Reikvam H. Febrile neutropenia in acute leukemia. *Epidemiology, etiology, pathophysiology and treatment*. Vol. 11, *Mediterranean Journal of Hematology and Infectious Diseases*. Universita Cattolica del Sacro Cuore; 2020.
13. Kumar V, Sharma A. Neutrophils: Cinderella of innate immune system. Vol. 10, *International Immunopharmacology*. 2010. p. 1325–34.
14. Cassatella MA, Östberg NK, Tamassia N, Soehnlein O. Biological Roles of Neutrophil-Derived Granule Proteins and Cytokines. Vol. 40, *Trends in Immunology*. Elsevier Ltd; 2019. p. 648–64.
15. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Vol. 18, *Nature Reviews Immunology*. Nature Publishing Group; 2018. p. 134–47.
16. Ma Q, Steiger S. Neutrophils and extracellular traps in crystal-associated diseases. *Trends Mol Med*. 2024. p 0-15.

17. Nauseef WM, Borregaard N. Neutrophils at work. Vol. 15, *Nature Immunology*. Nature Publishing Group; 2014. p. 602–11.
18. Ann Q. Neutrophil Extracellular Traps: As Antimicrobial Peptides. *Oral Rehabilitation and Dentistry*. 2019 Sep 13;1–9.
19. Rosales C. Neutrophil: A cell with many roles in inflammation or several cell types? Vol. 9, *Frontiers in Physiology*. Frontiers Media S.A.; 2018.
20. Kobayashi Y. Neutrophil biology: An update. *EXCLI J*. 2015;14:220–7.
21. Neumann A, Völlger L, Berends ETM, Molhoek EM, Stapels DAC, Midon M, et al. Novel role of the antimicrobial peptide LL-37 in the protection of neutrophil extracellular Traps against degradation by bacterial nucleases. *J Innate Immun*. 2014 Nov 7;6(6):860–8.
22. Hans M, Madaan Hans V. Epithelial antimicrobial peptides: Guardian of the oral cavity. Vol. 2014, *International Journal of Peptides*. Hindawi Publishing Corporation; 2014.
23. Ahmed A, Siman-Tov G, Hall G, Bhalla N, Narayanan A. Human antimicrobial peptides as therapeutics for viral infections. *Viruses*. 2019;11(8):1–26.
24. van der Does AM, Bergman P, Agerberth B, Lindbom L. Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. *J Leukoc Biol*. 2012;92(4):735–42.
25. Sørensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. *Blood* [Internet]. 1997 Oct 1;90(7):2796–803.
26. Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. Vol. 368, *FEBS 15706 FEBS Letters*. 1995. Jul 10;368(1)173-6.

27. Nizet V, Gallo RL. Cathelicidins and innate defense against invasive bacterial infection. *Scand J Infect Dis*. 2003;35(9):670–6.
28. Wetering S Van, Tjabringa GS, Hiemstra PS. Interactions between neutrophil-derived antimicrobial peptides and airway epithelial cells. 2005;
29. Nilsson B olof. Peptides What can we learn about functional importance of human antimicrobial peptide LL-37 in the oral environment from severe congenital neutropenia (Kostmann disease)? *Peptides (NY)* [Internet]. 2020;128(April):170311.
30. Badr M, Hassan T, Sakr H, Karam N, Rahman DA, Shahbah D, et al. Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences. *Mol Clin Oncol*. 2016;5(3):300–6.
31. Logan C, Koura D, Taplitz R. Updates in infection risk and management in acute leukemia. *Hematology Am Soc Hematol Educ Program*. 2020 Dec;2020(1):135–9.
32. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. *Clin Infect Dis*. 1999 Sep;29(3):490–4.
33. Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston K V. Infections in the neutropenic patient--new views of an old problem. *Hematology Am Soc Hematol Educ Program*. 2001;113–39.
34. Giamarellou H, Antoniadou A. Infectious complications of febrile leukopenia. *Infect Dis Clin North Am*. 2001 Jun;15(2):457–82.
35. Oh SM, Byun JM, Chang E, Kang CK, Shin DY, Koh Y, et al. Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis. *Sci Rep*. 2021 Nov;11(1):22160.
36. Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations

- from the European Conference on Infections in Leukaemia. *J Antimicrob Chemother.* 2018 Dec;73(12):3221–30.
37. Schmiegelow K, Müller K, Mogensen SS, Mogensen PR, Wolthers BO, Stoltze UK, et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. *F1000Res.* 2017;6:444.
38. Inaba H, Pei D, Wolf J, Howard SC, Hayden RT, Go M, et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. *Ann Oncol.* 2017 Feb;28(2):386–92.
39. Zawitkowska J, Drabko K, Szmydki-Baran A, Zaucha-Prażmo A, Lejman M, Czyżewski K, et al. Infectious profile in children with ALL during chemotherapy: A report of study group for infections. *J Infect Chemother.* 2019 Oct;25(10):774–9.
40. Polish Ministry of Health. Common Guidelines for Group 1B Patients and Healthcare Professionals on Vaccination against COVID-19. 2021.
41. Ayudhia S, Zatil Izzah A, Arbi F, Fitri Yani Bagian Ilmu Kesehatan F. Status Vitamin D pada Anak dengan Leukemia Akut. Vol. 24, 51 *Sari Pediatri.* 2022.
42. Gunawan S, Homenta Rampengan N, Frans Joseph Mantik M, Homenta Rampengan T. Febrile neutropenia in childhood leukemia: Manado experience 1997–2006. Vol. 49, *Paediatrica Indonesiana VOLUME.* 2009.
43. Agnes M, Widjajanto H, Damayanti W, Ilmu B, Anak K, Kedokteran F, et al. Kejadian Demam Neutropeni pada Leukemia Limfoblastik Akut Anak di RSUP Dr. Sardjito Yogyakarta The Incidence of Febrile Neutropenia in Childhood Acute Lymphoblastic Leukemia In Dr. Sardjito Hospital Yogyakarta. Vol. 20, *Sari Pediatri.* 2019.
44. Erbaş İC, Çakıl Güzin A, Özdem Alataş Ş, Karaoğlu Asrak H, Akans İ, Akyol Ş, et al. Etiology and Factors Affecting Severe Complications and Mortality of Febrile Neutropenia in Children with Acute Leukemia. *Turk J Haematol.* 2023 Aug 31;40(3):143–53.

45. Rolston KVI. Infections in patients with acute leukemia. In: *Infections in Hematology*. Springer Berlin Heidelberg; 2015. p. 3–23.
46. Mulatsih Sri. Demam Netropenia pada Kanker Anak, Buku Ajar Hematoonkologi Anak. WIndiastuti E, Nancy YM, Mulasih S, Sudarmanto B, Ugrasena IDG, editors. Jakarta: Ikatan Dokter Anak Indonesia; 2018. p. 369.
47. Nguyen SN, Vu LT, Vu Q Van, Tran TT, Dinh VTT. Clinical Epidemiology Characteristics and Etiology of Febrile Neutropenia in Children: Analysis of 421 Cases. *Hematol Rep*. 2022 Sep 1;14(3):245–52.
48. Carlesse F, Lopes de Sousa AV. Infections in children and adolescents with Acute Leukemia. *EJC Paediatric Oncology*. 2024 Jun;3:100142.
49. Mörtberg A, Pütsep K, Höglund P. The blood protein hCAP-18 in neutropenia: An 18-month experience of a new ELISA for clinical use. *Scand J Immunol*. 2021 Jul 1;94(1).
50. Kara SS, Tezer H, Polat M, Cura Yayla BC, Bedir Demirdağ T, Okur A, et al. Risk factors for bacteremia in children with febrile neutropenia. *Turk J Med Sci*. 2019 Aug 8;49(4):1198–205.
51. Rondinelli PIP, Ribeiro K de CB, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. *J Pediatr Hematol Oncol*. 2006 Oct;28(10):665–70.
52. Freifeld AG, Pizzo PA. The outpatient management of febrile neutropenia in cancer patients. *Oncology (Williston Park)*. 1996 Apr;10(4):599–606, 611–2; discussion 615-6.
53. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever--Reply. *Journal of Infectious Diseases*. 1991 Jan 1;163(1):202–3.

54. Regazzoni CJ, Khoury M, Irrazabal C, Myburg C, Galvalisi NR, O'Flaherty M, et al. Neutropenia and the development of the systemic inflammatory response syndrome. *Intensive Care Med.* 2003 Jan;29(1):135–8.
55. Berger Velten D, Zandonade E, Monteiro de Barros Miotto MH. Prevalence of oral manifestations in children and adolescents with cancer submitted to chemotherapy. *BMC Oral Health.* 2016 Oct 3;16(1):107.
56. Sereephinan C, Kanchanasuwan S, Julamanee J. Mortality-associated clinical risk factors in patients with febrile neutropenia: A retrospective study. *IJID Regions.* 2021 Dec;1:5–11.

